Patents Represented by Attorney Myriad IP Dept.
-
Patent number: 7345040Abstract: Reverse-turn mimetics and methods relating to the same having the following structure are disclosed: including pharmaceutically acceptable salts and stereoisomers thereof, wherein R1, R2, R3 and R4 are as defined herein. Such compounds have utility over a wide range of applications, including use as diagnostic and therapeutic agents. In particular, compounds of this invention, and pharmaceutical compositions containing such compounds, are neurokinin (tachykinin) antagonists. Libraries containing the reverse-turn mimetics of this invention are also disclosed.Type: GrantFiled: April 18, 2005Date of Patent: March 18, 2008Assignee: Myriad Genetics, Inc.Inventors: Maher N. Qabar, Marcin Stasiak, Jessymol Mathew, Thomas Little, Danwen Huang
-
Patent number: 7297515Abstract: Novel zinc finger proteins and nucleic acids encoding the proteins are provided. The zinc finger proteins interact with ZNF202, a zinc finger protein that regulates the expression of a variety of genes involved in lipid metabolism and transportation. Modulation of the novel zinc finger proteins and their interactions with ZNF202 can be useful in the treatment of coronary heart diseases, dyslipidemia, dyscholesterolemia and obesity.Type: GrantFiled: October 28, 2002Date of Patent: November 20, 2007Assignee: Myriad Genetics, Inc.Inventors: Philippe Szankasi, Kimberly Mauck, Daniel Albert Wettstein
-
Patent number: 6960431Abstract: Methods for inhibiting viral propagation and treating viral infection are provided which include administering to cells infected with viruses a therapeutic peptide or a derivative thereof.Type: GrantFiled: August 22, 2002Date of Patent: November 1, 2005Assignee: Myriad Genetics, Inc.Inventors: Scott Morham, Kenton Zavitz, Adrian Hobden
-
Patent number: 6895337Abstract: Methods, computer program products and systems are provided for detecting large genomic rearrangements based on unphased genotype data obtained using common genotyping techniques that do not differentiate different alleles. In the method, unphased genotypes at a plurality of nucleotide variant markers of a particular gene in a diploid subject are compared with a canonical haplotype collection of the gene for a heterogeneous subject population. If the unphased genotypes cannot be reduced to a pair of canonical haplotypes within the canonical haplotype collection, it would indicate an increased likelihood that an allele of the gene in the diploid subject harbors a genomic rearrangement.Type: GrantFiled: October 15, 2002Date of Patent: May 17, 2005Assignee: Myriad Genetics, Inc.Inventors: Thomas Scholl, Dmitry Pruss, Brant C. Hendrickson
-
Patent number: 6841352Abstract: The present invention provides a mating-based yeast two-hybrid system for determining whether a test polypeptide interacts with another test polypeptide in the presence or absence of one or more test compounds. The system is useful in detecting protein-protein interactions and in identifying compounds capable of modulating protein-protein interactions.Type: GrantFiled: June 28, 2002Date of Patent: January 11, 2005Assignee: Myriad Genetics, Inc.Inventor: Kirill Ostanin
-
Patent number: 6831154Abstract: Protein complexes are provided comprising MAP17 and SCAMP2. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with MAP17 and SCAMP2. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.Type: GrantFiled: May 14, 2002Date of Patent: December 14, 2004Assignee: Myriad Genetics, Inc.Inventor: Paul Bartel
-
Patent number: 6828421Abstract: Protein complexes are provided comprising VAP-A and one or more VAP-A-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with VAP-A and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.Type: GrantFiled: May 14, 2002Date of Patent: December 7, 2004Assignee: Myriad Genetics, Inc.Inventor: Janice Sugiyama
-
Patent number: 6828112Abstract: A method for detecting protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other. The interaction between the two fusion proteins leads to protein trans-splicing, generating an active and detectable reporter.Type: GrantFiled: January 4, 2002Date of Patent: December 7, 2004Assignee: Myriad Genetics, Inc.Inventors: John Manfredi, Jay Zhang
-
Patent number: 6653102Abstract: The present invention relates to the discovery of protein—protein interactions that are involved in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD). Thus, the present invention is directed to complexes of these proteins and/or their fragments, antibodies to the complexes, diagnosis of neurodegenerative disorders (including diagnosis of a predisposition to and diagnosis of the existence of the disorder), drug screening for agents which modulate the interaction of proteins described herein, and identification of additional proteins in the pathway common to the proteins described herein.Type: GrantFiled: October 11, 2001Date of Patent: November 25, 2003Assignee: Myriad Genetics, Inc.Inventors: Jean-Marc Roch, Paul L. Bartel, Karen Heichman, Kimberly Mauck, Max Dufford
-
Patent number: 6562576Abstract: A method for detecting protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other in yeast cells. The interaction between the two fusion proteins leads to protein trans-splicing, generating an active and detectable reporter.Type: GrantFiled: January 4, 2002Date of Patent: May 13, 2003Assignee: Myriad Genetics, Inc.Inventor: John Manfredi
-
Patent number: 6551786Abstract: A method for selecting compounds capable of modulating protein-protein interactions is provided, in which two fusion proteins are prepared and allowed to interact with each other in the presence of test compounds. The interaction between the two fusion proteins leads to protein trans-splicing, producing an active reporter. Compounds that disrupt or enhance protein-protein interactions can be selected based on the presence or absence of the active reporter.Type: GrantFiled: January 4, 2002Date of Patent: April 22, 2003Assignee: Myriad Genetics, Inc.Inventor: John Manfredi